Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $117.43 USD
Change Today +2.02 / 1.75%
Volume 339.3K
As of 11:27 AM 11/27/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

1801 Augustine Cut-Off

Wilmington, DE 19803

United States

Phone: 302-498-6700


Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development and commercialization of proprietary therapeutics to treat serious unmet medical needs, primarily in oncology. JAKAFI (ruxolitinib) JAKAFI (ruxolitinib) is the company’s first product to be approved for sale in the United States. It was approved by the U.S. Food and Drug Administration (FDA) in 2011 for the treatment of patients with intermediate or high-risk myelofibrosis and in 2014 for the treatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea. Myelofibrosis and polycythemia vera are both rare blood cancers. JAKAFI is marketed in the United States through the company’s own specialty sales force and commercial team. Under its collaboration agreement with Novartis International Pharmaceutical Ltd. (Novartis), Novartis received exclusive development and commercialization rights to ruxolitinib outside of the United States for all hematologic and oncologic indications and sells ruxolitinib outside of the United States under the name JAKAVI. To help ensure that all eligible myelofibrosis and polycythemia vera patients have access to JAKAFI, the company has established a patient assistance program called IncyteCARES (CARES stands for Connecting to Access, Reimbursement, Education and Support). IncyteCARES helps ensure that any patient with intermediate or high-risk myelofibrosis or uncontrolled polycythemia vera who meets certain eligibility criteria and is prescribed JAKAFI has access to the product regardless of ability to pay and has access to ongoing support and educational resources during treatment. In addition, IncyteCARES works with payers to help facilitate insurance coverage of JAKAFI. JAKAFI is distributed primarily through a network of specialty pharmacy providers and group purchasing organizations that allow for the delivery of the medication by mail directly to patients or direct delivery to the patient's pharmacy of choice. The company’s distribution process uses a model that is familiar to physicians who practice within the oncology field. Novartis received approval for JAKAVI in the European Union and Canada in 2012 for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis. JAKAVI is approved for myelofibrosis in approximately 70 countries with additional worldwide regulatory filings underway for both myelofibrosis and polycythemia vera. Clinical Programs JAK1/JAK2 Programs for Oncology and Inflammation The company and the FDA have agreed on an SPA (Special Protocol Assessment) for a registration trial for advanced or metastatic pancreatic cancer. Under the SPA, the Phase III JANUS 1 trial could be limited to patients with elevated C-reactive protein and there is no requirement to develop a companion diagnostic. The global Phase III program includes a second identical Phase III trial, JANUS 2. Both JANUS trials are recruiting patients. The company has a second JAK1 and JAK2 inhibitor, baricitinib, which is subject to its collaboration agreement with Eli Lilly and Company. JAK1 Programs for Oncology The company has a wholly owned portfolio of JAK1 inhibitors and is pursuing oncologic indications with its lead JAK1 inhibitor, INCB39110. The company has completed a Phase I clinical trial to evaluate the safety and tolerability of INCB39110 in combination with chemotherapy in patients with advanced solid tumors, and has initiated two planned placebo-controlled proof-of-concept Phase II trials of INCB39110 in distinct chemotherapeutic regimens in patients with non-small cell lung cancer. The company plans to begin a first line pancreatic cancer study of INCB39110 in combination with gemcitabine and nab-paclitaxel in the second half of 2015. It has another JAK1 inhibitor, INCB52793, which has initiated a Phase I/II trial in advanced malignancies. IDO1 for Oncology The company has four clinical trial agreements in place to evaluate the safety and efficacy of epacadostat in combination with four d


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INCY:US $117.43 USD +2.02

INCY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $75.78 USD +1.72
ARIAD Pharmaceuticals Inc $6.45 USD -0.07
BioMarin Pharmaceutical Inc $95.68 USD -0.38
Jazz Pharmaceuticals PLC $150.19 USD -0.26
Vertex Pharmaceuticals Inc $132.91 USD +0.94
View Industry Companies

Industry Analysis


Industry Average

Valuation INCY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 33.0x
Price/Book 241.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 31.9x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact INCYTE CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at